| |
| |
|
| Insider
Information: |
Schobel Alexander Mark |
| Relationship: |
|
| City: |
Warren |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
984,476 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,170,013 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
984,476 |
|
|
| Total
Value |
$3,170,013 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -14.7%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Aquestive Therapeutics, Inc. |
AQST |
|
2024-03-15 |
984,476 |
2018-08-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2024-03-15 |
4 |
AS |
$6.00 |
$300,000 |
D/D |
(50,000) |
984,476 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2024-03-09 |
4 |
D |
$4.88 |
$28,768 |
D/D |
(5,895) |
1,034,476 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2024-03-08 |
4 |
AS |
$5.19 |
$129,685 |
D/D |
(25,000) |
1,040,371 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2024-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
82,500 |
1,065,371 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2023-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
982,871 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2022-06-08 |
4 |
B |
$0.96 |
$44,036 |
D/D |
45,871 |
882,871 |
2.74 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2021-02-10 |
4 |
AS |
$6.75 |
$158,355 |
D/D |
(23,460) |
837,000 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2021-02-09 |
4 |
AS |
$6.75 |
$77,895 |
D/D |
(11,540) |
860,460 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2021-02-08 |
4 |
AS |
$6.50 |
$265,148 |
D/D |
(40,792) |
872,000 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-06-30 |
4 |
D |
$4.86 |
$457 |
D/D |
(94) |
912,792 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
333 |
912,886 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
916,685 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-05-31 |
4 |
D |
$4.87 |
$20,123 |
D/D |
(4,132) |
912,553 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-05-08 |
4 |
AS |
$5.00 |
$200,000 |
D/D |
(40,000) |
902,113 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-04-29 |
4 |
AS |
$4.50 |
$180,000 |
D/D |
(40,000) |
1,022,113 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-04-27 |
4 |
AS |
$4.00 |
$160,000 |
D/D |
(40,000) |
942,113 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-04-14 |
4 |
AS |
$3.70 |
$148,000 |
D/D |
(40,000) |
982,113 |
0 |
% |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-03-31 |
4 |
D |
$2.19 |
$212 |
D/D |
(97) |
1,062,113 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,062,210 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-02-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,572 |
1,066,947 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2020-02-29 |
4 |
D |
$3.73 |
$18,896 |
D/D |
(5,066) |
1,061,881 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2019-12-31 |
4/A |
D |
$5.82 |
$856 |
D/D |
(147) |
1,052,375 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2019-12-31 |
4 |
D |
$5.82 |
$1,915 |
D/D |
(329) |
1,044,165 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
329 |
1,044,494 |
0 |
- |
|
| AQST |
Aquestive Therapeutics, I... |
Chief Innovation/Tech Officer |
• – – |
2019-11-30 |
4 |
D |
$7.79 |
$113,516 |
D/D |
(14,572) |
1,044,165 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
